|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ni CY, Murphy MP, Golde TE and Carpenter
G: gamma-Secretase cleavage and nuclear localization of ErbB-4
receptor tyrosine kinase. Science. 294:2179–2181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan WL, Jain A, Takano A, Newell EW, Iyer
NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, et al: Novel
therapeutic targets on the horizon for lung cancer. Lancet Oncol.
17:e347–e362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z,
Liu C, Shen B, Wang XA, Wu W, et al: Whole-exome and targeted gene
sequencing of gallbladder carcinoma identifies recurrent mutations
in the ErbB pathway. Nat Genet. 46:872–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vlacich G and Coffey RJ: Resistance to
EGFR-targeted therapy: A family affair. Cancer Cell. 20:423–425.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hegde GV, de la Cruz CC, Chiu C, Alag N,
Schaefer G, Crocker L, Ross S, Goldenberg D, Merchant M, Tien J, et
al: Blocking NRG1 and other ligand-mediated Her4 signaling enhances
the magnitude and duration of the chemotherapeutic response of
non-small cell lung cancer. Sci Transl Med. 5:171ra182013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Settleman J: A therapeutic opportunity in
melanoma: ErbB4 makes a mark on skin. Cancer Cell. 16:278–279.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X, Li L, Tian T, Liu H, Li Q and Gao Q:
Study of lung cancer regulatory network that involves erbB4 and
tumor marker gene. Saudi J Biol Sci. 24:649–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Broughton MN, Westgaard A, Paus E,
Øijordsbakken M, Henanger KJ, Naume B and Bjøro T: Specific
antibodies and sensitive immunoassays for the human epidermal
growth factor receptors (HER2, HER3, and HER4). Tumour Biol.
39:10104283177074362017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song G, Zhang H, Chen C, Gong L, Chen B,
Zhao S, Shi J, Xu J and Ye Z: miR-551b regulates
epithelial-mesenchymal transition and metastasis of gastric cancer
by inhibiting ERBB4 expression. Oncotarget. 8:45725–45735.
2017.PubMed/NCBI
|
|
15
|
Zhang M, Zhang L, Cui M, Ye W, Zhang P,
Zhou S and Wang J: miR-302b inhibits cancer-related inflammation by
targeting ERBB4, IRF2 and CXCR4 in esophageal cancer. Oncotarget.
8:49053–49063. 2017.PubMed/NCBI
|
|
16
|
Ohashi Y, Kumagai K, Miyata Y, Matsubara
R, Kitaura K, Suzuki S, Hamada Y and Suzuki R: Overexpression of
ErbB4 is an independent marker for lymph node metastasis in
Japanese patients with oral squamous cell carcinoma. Oral Surg Oral
Med Oral Pathol Oral Radiol. 122:313–321. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ueda Y, Fujishima H, Hirashita T,
Shiroshita H, Etoh T, Inomata M and Shiraishi N: Clinical impact of
small advanced gastric cancer (≤40 mm) in elderly patients: A
retrospective cohort study. Int J Surg. 45:131–137. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pereira MA, Ramos MFKP, Dias AR, Faraj SF,
Yagi OK, Safatle-Ribeiro AV, Maluf-Filho F, Zilberstein B,
Cecconello I, de Mello ES, et al: Risk factors for lymph node
metastasis in western early gastric cancer after optimal surgical
treatment. J Gastrointest Surg. 22:23–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang JY, Shim KN, Tae CH, Lee KE, Lee J,
Lee KH, Moon CM, Kim SE, Jung HK, Jung SA, et al: Comparison of
clinical outcomes after endoscopic submucosal dissection and
surgery in the treatment of early gastric cancer: A
single-institute study. Medicine (Baltimore). 96:e72102017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bang CS, Park JM, Baik GH, Park JJ, Joo
MK, Jang JY, Jeon SW, Choi SC, Sung JK and Cho KB: Therapeutic
outcomes of endoscopic resection of early gastric cancer with
undifferentiated-type histology: A Korean ESD Registry Database
analysis. Clin Endosc. 50:569–577. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pinto C, Di Fabio F, Barone C, Siena S,
Falcone A, Cascinu S, Llimpe Rojas FL, Stella G, Schinzari G,
Artale S, et al: Phase II study of cetuximab in combination with
cisplatin and docetaxel in patients with untreated advanced gastric
or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J
Cancer. 101:1261–1268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun GP, Sun Y, Xu RH, Xu JM, Li J, Wang
JW, Qin S, Feng JF, Ba Y, Shen L, et al: The Chinese subgroup from
a randomized phase III study of lapatinib in combination with
weekly paclitaxel versus weekly paclitaxel alone as second-line
treatment of HER2-amplified advanced gastric cancer (AGC) in Asian
countries. J Clin Oncol. 31 Suppl:a41092013.
|
|
24
|
Satoh T, Xu RH, Chung HC, Sun GP, Doi T,
Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al: Lapatinib plus
paclitaxel versus paclitaxel alone in the second-line treatment of
HER2-amplified advanced gastric cancer in Asian populations: TyTAN
- a randomized, phase III study. J Clin Oncol. 32:2039–2049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lieto E, Ferraraccio F, Orditura M,
Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F and Galizia G:
Expression of vascular endothelial growth factor (VEGF) and
epidermal growth factor receptor (EGFR) is an independent
prognostic indicator of worse outcome in gastric cancer patients.
Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chua TC and Merrett ND: Clinicopathologic
factors associated with HER2-positive gastric cancer and its impact
on survival outcomes - a systematic review. Int J Cancer.
130:2845–2856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayashi M, Inokuchi M, Takagi Y, Yamada H,
Kojima K, Kumagai J, Kawano T and Sugihara K: High expression of
HER3 is associated with a decreased survival in gastric cancer.
Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Zhou X, Xu H, He Z, Shi X and Wu S:
SLC34A2 regulates the proliferation, migration, and invasion of
human osteosarcoma cells through PTEN/PI3K/AKT signaling. DNA Cell
Biol. 36:775–780, Epub ahead of print. 2017.PubMed/NCBI
|
|
29
|
Liang L, Gao C, Li Y, Sun M, Xu J, Li H,
Jia L and Zhao Y: miR-125a-3p/FUT5-FUT6 axis mediates colorectal
cancer cell proliferation, migration, invasion and pathological
angiogenesis via PI3K-Akt pathway. Cell Death Dis. 8:e29682017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fruman DA, Snapper SB, Yballe CM, Davidson
L, Yu JY, Alt FW and Cantley LC: Impaired B cell development and
proliferation in absence of phosphoinositide 3-kinase p85alpha.
Science. 283:393–397. 1999. View Article : Google Scholar : PubMed/NCBI
|
